ADVANCING THE PHARMACOLOGICAL TREATMENT OF TOBACCO AND NICOTINE DEPENDENCE

An independently-reviewed competitive grants program supported by Pfizer

PLEASE NOTE: THE GRAND PROGRAM IS NOW CLOSED

After a successful 10 years of annual competitive research awards, the GRAND program is no longer accepting new applications starting in 2018. Previously awarded research proposals will continue to be funded by the program sponsor, Pfizer Inc., until study completion. From 2007 to 2017, a total of 529 applications were received from investigators worldwide and 68 research proposals were funded for a total exceeding US $10 million.

During its 10 years of running, the mission of the GRAND program was to advance the pharmacological treatment of tobacco and nicotine dependence. Each year, applications from all over the world were formally assessed by an independent Review Committee comprising internationally prominent researchers in the field, led by the Co-Chairs John Hughes, MD, and Karl Fagerström, PhD.